We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





ERBA Group Launches New Hematology Analyzers at MEDLAB 2019

By Theresa Herman, Regional Director
Posted on 27 Mar 2019
Print article
Image: ERBA Diagnostics Mannheim launched its latest hematology analyzers at MedLab Middle East (Photo courtesy of ERBA).
Image: ERBA Diagnostics Mannheim launched its latest hematology analyzers at MedLab Middle East (Photo courtesy of ERBA).
ERBA Diagnostics Mannheim GmbH (Mannheim, Germany) launched its latest hematology analyzers at MedLab Middle East, an international platform for laboratory management and medicine that was held between February 4-7, 2019, at the Dubai International Convention and Exhibition Centre, Dubai, UAE.

ERBA is a global in-vitro diagnostic company that provides a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, hemostasis, critical care, electrophoresis, urine analysis, diabetes monitoring, autoimmune & infectious disease monitoring and microbiology. Its latest hematology analyzers, H 360 and H 560, launched at MedLab 2019 are designed for improving lab efficiency and are targeted at small to medium laboratories.

The newly launched, H 360 3-part differential analyzer can run up to 60 samples/hour and requires only 9 microliters of blood. The H 560 5-part differential analyzer also runs 60 samples/hour and requires only 15 microliters, which is highly beneficial in pediatric cases. In both systems, interpretation of results is aided using an advanced 3D scattergram. At MedLab 2019, ERBA also displayed the latest version of its fully automated urine chemistry and sediment analyzer, Laura XL which uses digital microscopy and AI technology to auto-recognize 16 urine sediment elements. Moreover, the photometric urine strip reader aids in the precise determination of 10 analytes using ERBA’s standardized test strips DekaPHAN.

ERBA’s team of experts provided a first-hand experience to the delegates on the new systems with more than 10 demonstrations being conducted each day. During the exhibition, customer interactions were complemented by a series of informational presentations conducted by industry experts and ERBA team members. Insightful discussions on the benefits of fast reporting for better treatment outcomes, validation methods for clinical chemistry systems, and the advantages of AMH ELISA testing were held, in addition to presentations on Laura XL, H 360 and 560 and the ELISA test range made by its US subsidiary, Calbiotech Inc.

“We are glad to be associated with MedLab as it offers an opportunity to interact with customers from across the world,” said Nikhil Vazirani, CEO, ERBA Group. “ERBA operates in a dynamic global economy and MedLab gives us a great opportunity to help understand changing customer needs and how we should adapt our technologies to offer seamless services. We are committed to focusing our products and solutions on the emerging markets and impacting a billion lives globally.”


New
Gold Supplier
Creatinine/eGFR Meter
Nova Max Pro
New
Allergen-Specific IgG/IgG4 Enzymimmunoassay
ALLERgen Specific IgG/IgG4 ELISA Kits
New
5-Diff Auto Hematology Analyzer
iCell-8800
New
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.